[1]Knopman DS,Parisi JE,Boeve BF,et al.Vascular dementia in a population-based autopsy study[J].Arch Neuro L,2003,60(4):569-575.
[2]Tariot PN.Contemporary issues in the treatment of Alzheimers'disease: angible benefits of current therapies[J].Clin Psychia-try,2006,67 (Suppl 3): 15-22.
[3]American Psychiatry Association.Diagnostic and statistical manual formental disorders-DSM-IV [M].4th ed. Washington: American Psychiattic Press,1994: 147-154.
[4]陈俊抛,周光斗.中西医结合脑血管病治疗学[M].北京:人民军医出版社,2004:287-290.
[5]Berr C,Wancata J,Ritchie K.Prevalence of dementia in the elderly in Europe[J].Eur Neuropsychopharmacol,2005,15(4):463-471.
[6]Ferri CP,Prince M,Brayne C,et al.Global prevalence of dementia:a Delphi consensus study[J].Lancet,2005,366(9503):2112-2117.
[7]Roman GC.Vascular dementia may be the most common foam of dementia in the elderly [J].J Neurol Sci,2002,203(4):7-10.
[8]Mobius HJ,Stoffler A.New approaches to clinical trials in vascular dementia memantine in small vessel disease[J].Cerebrovasc Dis,2002,13(2):61-66.
[9]Smith M,Wells J,Borrie M.Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia[J].Alzheimer Dis Assoc Disord,2006,20(3):133-137.
[10]Lopez-Arrieta JM,Birks J.Nimodipine for primary degenerative,mixed and vascular dementia[J].Cochrane Database Syst Rev,2002,3:147.
[11]Pantoni L,del Ser T,Soglian AG,et al.Efficacy and safety of nimodipine in subcortical vascular dementia:a randomized placebo-controlled trial[J].Stroke,2005,36(3):619-624.